

VAXXON® IBD imc

A complete cycle of protection in the control of Gumboro Disease



- One single vaccination in hatchery
- *In ovo* or subcutaneous vaccination
- Individual and lifelong protection

vaxxino[®]

Gumboro disease – huge economic impact

Infectious Bursal Disease (IBD), more commonly referred to as Gumboro disease, is an acute highly contagious viral infection in immature young chickens. IBD is characterized by destruction of lymphocytes in the bursa of Fabricius (BF) and to a lesser extent in other lymphoid organs. Important to remind is that the virus is resistant to many disinfectants and environmental factors. A disease likely to cause huge economical losses.

Prevention


The two most important pillars in the prevention of IBD are:

1. Implement and adhere to a biosecurity program.
2. An effective vaccination strategy, which includes the correct choice of the vaccine strain and the vaccination process.

VAXXON® IBD imc – complete protection

Vaxxinova's IBDv immune complex vaccine for broiler vaccination. Provides **early onset of immunity and a lifelong protection with one vaccination**, applied *in ovo* to 18-19 day-old embryos or subcutaneously to 1-day-old broiler chicks. VAXXON® IBD imc offers bird individual protection and is safe to use, regardless the level of maternal antibodies present.

Immune response profile VAXXON® IBD imc



Immune complex vaccine against Infectious Bursal Disease, from Vaxxinova, consists of live attenuated virus from chicken embryo origin, **Winterfield 2512 strain**, prepared in Specific Pathogen Free eggs (SPF) and the serum. Each dose of the vaccine contains, within the expiration date (24 months):

- Infectious Bursal Disease (IBD) virus with a minimum titre of $10^{2.5}$ EID₅₀ plus a concentration of antibodies against the Infectious Bursal Disease Virus (Ab-IBD) $\gg 0.005$ UN/ml*.

*Related to bulk vaccine before freeze-drying.

VAXXON® IBD imc - Immune complex vaccine against Infectious Bursal Disease, for chicken

broilers

Target Species

Chickens, 18- to 19 day-old embryonated broiler hatching eggs or one-day-old broiler chicks.

Pharmaceutical form

Lyophilised (freeze-dried) vaccine for injection.

Indications

For the active immunization of one-day-old broilers chicks or 18- to 19-day-old embryonated broiler hatching eggs, with IBD maternal antibodies against Infectious Bursal Disease, to reduce clinical signs of disease caused by very virulent Avian Infectious Bursal Disease (IBD) viruses.

Dosage and method of administration

Subcutaneous The recommended dose of the reconstituted vaccine for 1 (one) day old chickens is 0.2 ml.

In ovo administration The recommended dose of the reconstituted vaccine for embryonated eggs with 18 (eighteen) to 19 (nineteen) days of incubation is 0.05 ml.

in ovo / subcutaneous

Package size

The lyophilisate is presented in glass vials containing 1000, 2000, 2500, 3000, 4000, 5000 or 10000 doses.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 24 months.

Shelf life after reconstitution: use immediately.

complete cycle of protection

Storage conditions

Store and transport refrigerated (2°C – 8°C). Do not freeze. Protect from light.

IBD imc



Disclaimer

This brochure may contain information or may show or refer to products and/or services which are only available in certain countries. A reference to any product/service in this brochure does not imply that such product/service with the same specifications etcetera, is or will be available at your location. Any product shown or referred to in this brochure may be subject to different regulatory requirements depending on the country of use.

Please contact your local Vaxxinova representative for more information.

Vaxxinova® International BV does not give any warranty or other assurance as to the content of this brochure, its accuracy, completeness, timelessness or fitness for any particular purpose. To the full extent permissible by law, Vaxxinova International BV disclaims all responsibility for any damages or losses (including without limitation, financial loss, damages for loss in business projects, loss of profits or other consequential losses) arising in contract, tort or otherwise from the use of inability to use any material of Vaxxinova, or from any action or decision taken as a result of using Vaxxinova's materials. Vaxxinova disclaims all responsibility and liability (including for negligence) in relation to information mentioned in Vaxxinova's materials. This document or its content is not to be copied or further distributed without the consent of Vaxxinova International BV.

VAXXINOVA, VAXXON and GOVAXX are registered trademarks of Vaxxinova International B.V. (the Netherlands).

Version number 02, 2022.12 Product number 131796

Vaxxinova® International BV

Transistorweg 5
6534 AT Nijmegen, The Netherlands
+31 24 20 48 600, info@vaxxinova.com
www.vaxxinova.com